Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms SELECT
- Sponsors Eisai Inc
- 05 Apr 2022 Results (n=261)assessing impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer, published in the Cancer
- 29 Apr 2021 According to an Eisai Inc media release, results of post hoc analysis of patients with differentiated thyroid cancer have been published in the European Journal of Cancer.
- 29 Apr 2021 Results of post hoc analysis from patients with differentiated thyroid cancer, presented in an Eisai Inc media release.